Skip to content
Home/Companies/Biotech/Epsilogen
Epsilogen

Epsilogen

Biotech·UK·Active·8yr hold
Entry
2018
Hold
8yr
Status
Active

Who owns Epsilogen?

Epsilogen is currently owned by ALSA Ventures through ALSA Ventures European Biotechnology Fund (2020 vintage), since 2018.

Hand-verified · updated 2026-05-22

ALSA Ventures
Investor
ALSA Ventures
ALSA Ventures European Biotechnology Fund · 2020 · Life Sciences VC

Key facts

HQUK
SectorBiotech
StatusActive
Websiteepsilogen.com

More from ALSA Ventures European Biotechnology Fund

Other portfolio companies in the same fund.

ReproNovo
Active
BiotechSwitzerland· 2025
Axovia Therapeutics
Axovia Therapeutics
Active
BiotechUK· 2023
Vantage Biosciences
Vantage Biosciences
Active
BiotechUK· 2023
Promatix
Active
BiotechUK· 2021
Montis Biosciences
Montis Biosciences
Active
BiotechBelgium· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Epsilogen

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Epsilogen?

5 strategic and 115financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Epsilogen.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue